Showing 1671-1680 of 10489 results for "".
Learn More About REVIAN® Red Hair Growth System
https://practicaldermatology.com/topics/hair-nails/learn-more-about-revian-red-hair-growth-system/19750/Discover a new option for hair loss patients! REVIAN Red is a patented dual-band LED wireless cap for at-home use ten minutes daily. Click Here to Become a REVIAN Red Professional. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton clElastin - The underappreciated skin fundamental
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/elastin-the-underappreciated-skin-fundamental/19672/Join Macrene Alexiades, MD, PhD, FAAD as she discusses elastin and its role as a critical, yet often underappreciated, skin fundamental. In this webinar, she explains why lack of elastin is the root cause of skin laxity and what happens when there is a cessation of elastin synthesis. Dr. Alexiades rDermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician ADermWireTV: PCA to Space Station; ASDS Pandemic Data; LaRoche-Posay, GW Partnership
https://practicaldermatology.com/topics/practice-management/dermwiretv-pca-to-space-station-asds-pandemic-data-laroche-posay-gw-partnership/20059/The "Great Resignation" forcing some dermatology practices to operate with reduced staffing is just one of the lingering impacts of the COVID-19 pandemic on practices, according to results of a survey by the American Society for Dermatologic Surgery. PCA skin is sending the first-ever private sectorUpdates from Principia, Sebacia, and Candela
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-principia-sebacia-and-candela/19571/Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranExploring the Benefits of Nitric Oxide for Hair Loss Patients Through REVIAN® Red
https://practicaldermatology.com/topics/hair-nails/exploring-the-benefits-of-nitric-oxide-for-hair-loss-patients-through-revian-red/19753/Learn more about the mechanism of action of the new REVIAN Red Dual-Band LED light therapy cap and what makes it unique from other at-home FDA-cleared devices. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIaNoah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourDermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d